



Saamya Biotech (India) Ltd.

To,
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Date: 30.05.2019

Dear Sir / Madam,

Sub: Intimation of Board Meeting under regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Saamya Biotech(India) Limited (Scrip Code: 532905)

With reference to the subject cited, this is to inform the Exchange that meeting of the Board of Directors of Saamya Biotech(India)Limited will be held on Thursday, the 30th day of May, 2019, at 4.00 p.m. at the registered office of the company to consider the following:

1. Audited financial results for the quarter & year ended 31.03.2019.
2. Auditors Report for the quarter & year ended 31.03.2019
3. Any other business with the permission of the Chair.


This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For SaamyaBiotech(India)Limited

Y. Manivardhan Reddy

Yala Manivardhan Reddy
Director
(DIN:01368438)



Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta,
Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099
Web: www.saamyabiotech.net; **Email:** saamyaindia@saamyabiotech.net



Saamya Biotech (India) Ltd.

Statement of Assets and Liabilities			
(Amount in Lakhs.)			
	PARTICULARS	As at March 31, 2019	As at March 31, 2018
I	ASSETS:		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	17.27	17.27
	(b) Capital work-in-progress	1,825.99	1,825.99
	(c) Financial assets	-	-
	(i) Investments	0.89	0.89
	(ii) Other Financial Assets	-	-
	(d) Long term Loans & advances	-	-
	(e) Other non current Assets	-	-
	(f) Deferred Tax Assets(net)	15.99	15.99
(2)	Current assets		
	(a) Inventories	-	-
	(b) Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	1,861	1,861
	(v) Loans and advances	0.87	0.87
	(vi) Investments held for Sale	65.51	65.51
	(c) Other current assets	-	-
	TOTAL ASSETS	3,787.28	3,787.28
II	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	2,488.25	2,488.25
	(b) Other Equity	-	-
	(ii) Reserves and Surplus	(3,829.82)	(3,827.86)
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities	-	-
	(i) Borrowings	324.01	324.01
	(b) Provisions	-	-
(2)	Current Liabilities		
	(a) Financial Liabilities	-	-
	(i) Borrowings	-	-
	(ii) Trade Payables	4,679.63	4,679.63
	(iii) Other financial liabilities	-	-
	(b) Other current liabilities	7.87	7.87
	(c) Provisions	117.34	115.38
	(d) Current tax liabilities(Net)	-	-
	TOTAL EQUITY AND LIABILITIES	3,787.28	3,787.28

For SAAMYA BIOTECH (INDIA) LIMITED

Y. Manivardhan Reddy


YALA MANIVARDHAN REDDY

Director

DIN (01368438)

Place : Hyderabad

Date : 30-05-2019



Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta,
Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099
Web: www.saamyabiotech.net; **Email:** saamyaindia@saamyabiotech.net



Saamya Biotech (India) Ltd.

SCHEDULE III OF COMPANIES ACT, 2013

PART II - AUDITED STANDALONE & CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR QUARTER IV AND YEAR ENDED 31ST MARCH, 2019

Amounts in Lakhs

Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2019	Preceding 3 Months Ended 31/12/2018	Corsp. 3 moths ended 31/03/2018	31-03-2019	31-03-2018
	Audited	Unaudited	Audited	Audited	Audited
I Revenue from Operations	-	-	-	-	-
II Other Income	-	-	-	-	-
III Total Revenue (I+II)	-	-	-	-	-
IV Expenses					
Cost of Material Consumed	-	-	-	-	-
Purchase of Stock-in-trade	-	-	-	-	-
Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-
Employee benefits expense	0.15	0.15	-	0.96	2.00
Finance Costs	-	-	-	-	-
Depreciation and Amortisation expense	-	-	-	-	-
Other Expense	0.40	0.10	1.00	1.00	1.00
Total Expenses	0.55	0.25	1.00	1.96	3.00
V Profit/(Loss) from before Exceptional Items and tax (I-IV)	(0.55)	(0.25)	(1.00)	(1.96)	(3.00)
VI Exceptional Items	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(0.55)	(0.25)	(1.00)	(1.96)	(3.00)
VIII Tax Expense:					
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	-
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(0.55)	(0.25)	(1.00)	(1.96)	(3.00)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(0.55)	(0.25)	(1.00)	(1.96)	(3.00)
XIV Other Comprehensive Income A)					
(i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss	-	-	-	-	-
(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	-	-	-	-	-
XVI Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVII Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVIII Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XIX Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25
XX Reservers & Surplus (Excluding Revaluation Reserve)					

Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta,
Hyderabad - 82, Telangana, India, Ph: +91-40-2339 0099 / 3099 / 8099

Web: www.saamyabiotech.net; Email: saamyaindia@saamyabiotech.net



Maniandhan Reddy



Saamya Biotech (India) Ltd.


Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Friday, 31st May, 2019.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
4. The figures of the current quarter ended 31st March, 2019 and the quarter ended 31st March, 2018 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
5. The results are also available on the website of the Company www.saamyabiotechltd.com
6. The Company is engaged in " in the research and development of biotechnology products in India" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

For SAAMYA BIOTECH (INDIA) LIMITED

U. Manivardhan Reddy
YALA MANIVARDHAN REDDY
Director
DIN (01368438)

Place : Hyderabad
Date : 30-05-2019



Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta,
Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099
Web: www.saamyabiotech.net; **Email:** saamyaindia@saamyabiotech.net



Saamya Biotech (India) Ltd.


SAAMYA BIOTECH (INDIA) LIMITED

104-106, LUMBINI ENCLAVE, PUNJAGUTTA, HYDERABAD ANDHRA PRADESH Hyderabad AP 500082 IN
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2019

PARTICULARS	Year ended 31-03-2019 Amount in Rs.	Year ended 31-03-2018 Amount in Rs.
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax		
<u>Adjustment for:</u>	(1.96)	(3.03)
Depreciation and Amortisation	-	-
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(1.96)	(3.03)
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	-	-
(Increase)/Decrease in other Current Assets	-	-
(Increase) / Decrease in Inventories	-	-
Increase/ (Decrease) in Trade Payables	-	-
Increase / (Decrease) in Short Term Provision	-	2.00
Increase/(Decrease) in Other current liabilities	1.96	1.00
Change in Working Capital	-	-
	1.96	3.00
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in Other non Current Assets	-	-
Decrease/(Increase) in Long Term Provisions	-	-
Changes in non current assets and liabilities	-	-
<u>Cash Generated From Operations</u>		
Less: Taxes paid	-	(0.03)
Net Cash from operating activities(A)	-	(0.03)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	-	-
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	-	-
Interest paid	-	-
Net cash Flow from Financing Activities (C)	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	-	(0.03)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	0.87	0.91
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	0.87	0.87

For and on behalf of the Board of Directors
SAAMYA BIOTECH (INDIA) LIMITED

V. Manivardhan Reddy
YALA MANIVARDHAN REDDY
Director



Place : Hyderabad

Date : 30.05.2019

Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta, Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099

Web: www.saamyabiotech.net; Email: saamyaindia@saamyabiotech.net



M M REDDY & CO.,
Chartered Accountants

Phone : 040-23418836
040-40272617
Mobile : 98482 71555

Auditor's Report On Quarterly Standalone Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

Board of Directors

SAAMYA BIOTECH(INDIA) LIMITED

We have audited the quarterly financial results **SAAMYA BIOTECH(INDIA) LIMITED** for the quarter ended March 31, 2019 and for the year ended, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 for 'Interim Financial Reporting', specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides reasonable basis for our opinion.


In our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results, as well as the year to date results: _

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016 in this regard; and

(ii) give a true and fair view of the total comprehensive income (comprising of net profit and other comprehensive income) and other financial information for the quarter ended March 31, 2019 and for the year then ended.

For **M M REDDY & CO.,**
Chartered Accountants


M MADHUSUDHANA REDDY
Partner
Membership No. 213077



PLACE: HYDERABAD
DATE: 30/05/2019